drugset

drugset / Trial / NCT03287076

Trial of EXenatide in Acute Ischaemic Stroke

NCT03287076 ↗

Phase 2 Unknown 350 enrolled Neuroscience Trials Australia Monash University · collab National Health and Medical Research Council, Australia · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

A multicentre, randomised controlled Trial of Exenatide versus standard care in Acute Ischemic Stroke

Timeline

Start: 2017-11-23
Primary completion: 2021-10-04
Completion: 2021-12-31

Outcome

Missed primary endpoint

paper adjusted odds ratio, 1.22 [95% CI, 0.79-1.88]; P=0.38 PMID 38011235 ↗

paper Treatment with exenatide did not reduce neurological impairment at 7 days in patients with acute ischemic stroke. PMID 38011235 ↗

Publications

Bladin CF, Wah Cheung N, Dewey HM, Churilov L, Middleton S, Thijs V, Ekinci E, Levi CR, Lindley R, Donnan GA, Parsons MW, Meretoja A, Tiainen M, Choi PMC, Cordato D, Brown H, Campbell BCV, Davis SM, Cloud G, Grimley R, Lee-Archer M, Ghia D, Sanders L, Markus R, Muller C, Salvaris P, Wu T, Fink J; TEXAIS Investigators. Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial. Stroke. 2023 Dec;54(12):2962-2971. doi: 10.1161/STROKEAHA.123.044568. Epub 2023 Nov 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	5 ug	Subcutaneous

Indications